The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOEX.L Regulatory News (OEX)

  • There is currently no data for OEX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Replacement Appendix 5B

6 May 2020 07:00

RNS Number : 0521M
Oilex Ltd
06 May 2020
 

Appendix 5B

Mining exploration entity or oil and gas exploration entityquarterly cash flow report

Name of entity

OILEX LTD

ABN

 

Quarter ended ("current quarter")

50 078 652 632

 

31 MARCH 2020

 

Consolidated statement of cash flows

Current quarter$A'000

Year to date (9months)$A'000

1.

Cash flows from operating activities

-

-

1.1

Receipts from customers

1.2

Payments for

(353)

(787)

 

(a) exploration & evaluation (if expensed)

 

(b) development

-

-

 

(c) production

(47)

(154)

 

(d) staff costs

(203)

(618)

 

(e) administration and corporate costs

(334)

(712)

1.3

Dividends received (see note 3)

-

-

1.4

Interest received

0

1

1.5

Interest and other costs of finance paid

(2)

(23)

1.6

Income taxes paid

-

-

1.7

Government grants and tax incentives

-

-

1.8

Other (provide details if material)

-

-

1.9

Net cash from / (used in) operating activities

(939)

(2,293)

 

2.

Cash flows from investing activities

-

-

2.1

Payments to acquire:

 

(a) entities

 

(b) tenements

-

(122)

 

(c) property, plant and equipment

(2)

(4)

 

(d) exploration & evaluation (if capitalised)

-

-

 

(e) investments

-

-

 

(f) other non-current assets

-

-

2.2

Proceeds from the disposal of:

-

-

 

(a) entities

 

(b) tenements

-

-

 

(c) property, plant and equipment

-

-

 

(d) investments

-

-

 

(e) other non-current assets

-

-

2.3

Cash flows from loans to other entities

-

-

2.4

Dividends received (see note 3)

-

-

2.5

Other (provide details if material)

-

-

2.6

Net cash from / (used in) investing activities

(2)

(126)

 

3.

Cash flows from financing activities

330

2,315

3.1

Proceeds from issues of equity securities (excluding convertible debt securities)

3.2

Proceeds from issue of convertible debt securities

-

-

3.3

Proceeds from exercise of options

-

-

3.4

Transaction costs related to issues of equity securities or convertible debt securities

(40)

(181)

3.5

Proceeds from borrowings

381

381

3.6

Repayment of borrowings

-

(330)

3.7

Transaction costs related to loans and borrowings

-

-

3.8

Dividends paid

-

-

3.9

Other (provide details if material)

-

-

3.10

Net cash from / (used in) financing activities

671

2,185

 

4.

Net increase / (decrease) in cash and cash equivalents for the period

 

 

4.1

Cash and cash equivalents at beginning of period

402

358

4.2

Net cash from / (used in) operating activities (item 1.9 above)

(939)

(2,293)

4.3

Net cash from / (used in) investing activities (item 2.6 above)

(2)

(126)

4.4

Net cash from / (used in) financing activities (item 3.10 above)

671

2,185

4.5

Effect of movement in exchange rates on cash held

1

9

4.6

Cash and cash equivalents at end of period

133

133

 

5.

Reconciliation of cash and cash equivalentsat the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts

Current quarter$A'000

Previous quarter$A'000

5.1

Bank balances

133

402

5.2

Call deposits

-

-

5.3

Bank overdrafts

-

-

5.4

Other (provide details)

-

-

5.5

Cash and cash equivalents at end of quarter (should equal item 4.6 above)

133

402

 

6.

Payments to related parties of the entity and their associates

Current quarter$A'000

6.1

Aggregate amount of payments to related parties and their associates included in item 1

99

6.2

Aggregate amount of payments to related parties and their associates included in item 2

-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments

 

Director's fees, consulting fees and superannuation.

7.

Financing facilitiesNote: the term "facility' includes all forms of financing arrangements available to the entity.

Add notes as necessary for an understanding of the sources of finance available to the entity.

Total facility amount at quarter end$A'000

Amount drawn at quarter end$A'000

7.1

Loan facilities

950

640

7.2

Credit standby arrangements

-

-

7.3

Other (please specify)

-

-

7.4

Total financing facilities

950

640

 

 

 

7.5

Unused financing facilities available at quarter end

310

7.6

Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

Loan facility details:

· Series B facility $A250,000: Lender- Republic Investment Management Pte Ltd, fully drawn 26 September 2018, interest rate 5%, unsecured, repayment date extended to 31 July 2020.

· Series C facility GBP£125,000: Lender- Republic Investment Management Pte Ltd, amount drawn at quarter end GBP£60,000, interest rate 5%, unsecured, repayment date 1 August 2020.

· Series D facility GBP£225,000: Lender- Lombard Bank Malta plc, amount drawn at quarter end GBP£135,000, interest rate 5%, unsecured, repayment date extended from 1 August 2020 to 1 March 2021.

 

8.

Estimated cash available for future operating activities

$A'000

8.1

Net cash from / (used in) operating activities (Item 1.9)

(939)

8.2

Capitalised exploration & evaluation (Item 2.1(d))

-

8.3

Total relevant outgoings (Item 8.1 + Item 8.2)

(939)

8.4

Cash and cash equivalents at quarter end (Item 4.6)

133

8.5

Unused finance facilities available at quarter end (Item 7.5)

310

8.6

Total available funding (Item 8.4 + Item 8.5)

443

8.7

Estimated quarters of funding available (Item 8.6 divided by Item 8.3)

0.5

8.8

If Item 8.7 is less than 2 quarters, please provide answers to the following questions:

 

1. Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

 

Answer: Following the onset of Covid-19, the Company has substantially restructured its operating overheads whereby forecast cash outflows for the June quarter have been substantially reduced to approximately AUD325,000.

 

 

2. Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

 

Answer: Following the end of the quarter, the Company has already arranged an equity capital raising of GBP250,000. Further equity capital raisings will be considered in the September quarter, if required.

 

 

3. Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

 

Answer: Yes. The Company has limited operating expenditure planned for the next two quarters as summarised below:

 

India - The Company is in the final stages of implementing its Cambay settlement agreement with GSPC with field activities suspended pending completion of this settlement.

UKCS - The Company is awaiting government approval for the transfer of the Doyle-Peel licences by the OGA with no activities are planned pending the transfer.

Cooper- The Company is presently in detailed discussions for the proposed sale of its Cooper Basin assets.

 

 

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

 

 

Date: 5 May 2020

Authorised by: Mark Bolton - Executive Director

(Name of body or officer authorising release - see note 4)

 

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, AASB 6: Exploration for and Evaluation of Mineral Resources and AASB 107: Statement of Cash Flows apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standards apply to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee - eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's Corporate Governance Principles and Recommendations, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCKKABNKBKKDPK
Date   Source Headline
24th Aug 20177:00 amRNSCore Analysis and Review Confirms Cambay Potential
7th Aug 20177:00 amRNSExpiry of Unlisted Options
31st Jul 20177:49 amRNSSecurities Trading Policy
31st Jul 20177:00 amRNSQuarterly Report 30 June 2017
19th Jun 20177:00 amRNSTrading Halt
19th Jun 20177:00 amRNSPartial Receipt of Outstanding Cash Calls
6th Jun 20177:10 amRNSCambay PSC Workover and Project Update
30th May 20177:59 amRNSAppendix 3X P Haywood
30th May 20177:47 amRNSOilex Appoints New UK Based Non-Executive Director
23rd May 20177:00 amRNSCambay Production Update - C-73 and C-77
22nd May 20179:31 amRNSTranche 2 Unlisted Options Issued
12th May 201710:10 amRNSBhandut and Cambay Updates
10th May 20179:57 amRNSAppendix 3B Issue of Shares & Section 708 Notice
3rd May 20177:00 amRNSResults of 3 May 2017 General Meeting
28th Apr 20179:31 amRNSQuarterly Report 31 March 2017
28th Apr 20179:20 amRNSMobilisation of Workover Rig at Cambay
21st Apr 20178:19 amRNSChange of ASX Share Registry Address
21st Apr 20177:00 amRNSAward of Key Contracts Cambay-23z Core Analysis
18th Apr 20177:00 amRNSNotice of Change of Substantial Interest
6th Apr 20177:00 amRNSNotice of Change of Substantial Interest
4th Apr 20178:28 amRNSOilex Engagement via Vox Markets
3rd Apr 20177:00 amRNSNotice of General Meeting
31st Mar 20179:16 amRNSAppendix 3B Issue of Shares and Section 708 Notice
31st Mar 20177:00 amRNSOilex Investor Presentation April 2017
24th Mar 20177:00 amRNSAppendix 3B Issue of Shares and Section 708 Notice
17th Mar 20177:08 amRNSAppendix 3B
17th Mar 20177:00 amRNSAppendix 3Y J Salomon
17th Mar 20177:00 amRNSManaging Director - Contract Extension
16th Mar 20177:00 amRNSReinstatement to Official Quotation
16th Mar 20177:00 amRNSInterim Report 31 December 2016
15th Mar 201710:09 amRNSPlacement to Fund Cambay Work Programme
15th Mar 20177:00 amRNSSuspension of Trading on ASX
13th Mar 20177:00 amRNSTrading Halt
1st Mar 20177:00 amRNSCancellation of Unlisted Options
23rd Feb 20177:57 amRNSOilex Appoints New Chairman
13th Feb 20177:00 amRNSCancellation of Unlisted Options
30th Jan 20179:18 amRNSQuarterly Report 31 December 2016
30th Jan 20179:09 amRNSOilex Investor Presentation Jan Feb 2017
4th Jan 20177:00 amRNSCancellation of Unlisted Options
19th Dec 20167:00 amRNSAppendix 3B - Issue of Retention Rights
19th Dec 20167:00 amRNSAppendix 3Y J Salomon
13th Dec 20168:23 amRNSOilex tenders for 55% interest in Cambay PSC
6th Dec 20167:00 amRNSExpiry of Unlisted Options
24th Nov 20167:00 amRNSAppendix 3B
24th Nov 20167:00 amRNSAppendix 3Y J Salomon
23rd Nov 20167:00 amRNSChairman's Address to Shareholders
23rd Nov 20167:00 amRNSResults of Annual General Meeting 23 November 2016
23rd Nov 20167:00 amRNSWaiver of ASX Listing Rule 10.13.5
14th Nov 20167:00 amRNSExpiry of Unlisted Options
7th Nov 20167:00 amRNSExpiry of Unlisted Options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.